Pharmacokinetics and Dosimetry of Tc 99m Tilmanocept Following a Single Intravenous Dose Administration in Male and Female Subjects Diagnosed With Rheumatoid Arthritis (RA)

NCT03241446 · clinicaltrials.gov ↗

PHASE1

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped This study was combined with another trial that was on-going.

Conditions

Arthritis, Rheumatoid

Interventions

DRUG: Tilmanocept

Sponsor

Navidea Biopharmaceuticals